PTJ
AXSM icon

Paul Tudor Jones’s Axsome Therapeutics AXSM Stock Holding History

Paul Tudor Jones’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Buy
+1,700
New +$369K ﹤0.01% 2946

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Paul Tudor Jones's AXSM Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 18,950 shares worth $4.64M. The stake represents 0.01% of the portfolio and ranks #1330 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in AXSM as recently as Q1 2025.

Paul Tudor Jones first reported a position in AXSM in Q4 2019 and has held it in 17 quarters since. The position peaked at $4.77M in Q1 2025. 502 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Paul Tudor Jones held 18,950 shares of Axsome Therapeutics worth $4.64M as of Q2 2026.
  • Axsome Therapeutics was a new Paul Tudor Jones position in Q2 2026.
  • Axsome Therapeutics made up 0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1330 holding.
  • Paul Tudor Jones first reported a position in Axsome Therapeutics in Q4 2019 and has held it in 17 quarters since.
  • Paul Tudor Jones's Axsome Therapeutics position peaked at $4.77M in Q1 2025.
  • 502 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.